Covira
Sharon Ayd, Ph.D., MBA has extensive work experience in the pharmaceutical and biotech industries. Sharon founded Ayd BioPharma Consulting Group LLC in 2015, where they provide technical support and expert advice to life sciences companies regulated by the FDA. Additionally, they serve as a board member for Reglagene, a pre-clinical stage oncology and CNS company, and as a scientific advisor at The Ohio State University, focusing on translational science and clinical product development. Sharon also works as the Chief (Fractional) Regulatory Advisor at Covira, a biotech company focused on developing drugs that modulate the gut microbiome to prevent diseases. Sharon has previously held positions as the VP & Principal of the Regulatory Center of Excellence at Advarra, and as the Chief Science Officer and Executive Vice President at Regulatory Compliance Associates Inc. (RCA), where they built and expanded a pharma/biotech consulting practice. Sharon also has experience as the Global Vice President of Research and Development at Fresenius Kabi USA, where they turned around the operational performance of the Innovation & Development Center, and as the Chief Scientific Officer at Pinnacle Biologics, Inc., where they repurposed and revitalized an orphan-designated pipeline of oncology drugs. Sharon's earlier roles include Vice President of Quality at Regulatory Compliance Associates Inc. (RCA) and various positions at other pharmaceutical companies.
Sharon Ayd, Ph.D., MBA has a diverse education history. Sharon holds a Ph.D. in Pharmaceutics and Drug Design from the University of Illinois Chicago. Additionally, they obtained a Master of Science in Law - MSL from Northwestern University Pritzker School of Law, specializing in American/U.S. Law/Legal Studies/Jurisprudence. In 2019, they pursued a Master of Science - MS in Pharmaceutics and Drug Design at the University of Wisconsin-Madison.
Furthermore, in October 2016, Sharon Ayd completed the Board Room Ready Certification Course at The George Washington University, further enhancing their knowledge and skills in the field.
This person is not in any teams
This person is not in any offices
Covira
Covira Surgical engages in the development of drugs that modulate the biological activity of the gut microbiome's resident bacteria. It is based on the work of Dr. John Alverdy, MD, a world authority on the molecular basis of post-surgical infections. Covira’s platform technology generated a lead asset (CS-0003) that modulates bacterialvirulence and restores microbial communities to prevent post-surgical infection. Covira’s approach is transformative to the field and the world is taking notice...in the 4th quarter of last year, Business Worldwide Magazine named Covira Among the 2021 - Top 20 Most Innovative Companies to Watch.